© 2000 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Evidence for Association Between Polycystic Ovary Syndrome and Premature Carotid Atherosclerosis in Middle-Aged Women
From the Department of Epidemiology (E.O.T., K.S.-T., K.P.M.-P., J.V.Z., K.E.R., L.H.K.), University of Pittsburgh, Pittsburgh, Pa, and the Department of Obstetrics/Gynecology (D.S.G.), University of Rochester Medical Center, Rochester, NY.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder characterized by obesity, hyperandrogenism, and insulin resistance. An adverse lipid profile has also been observed in PCOS-affected women, suggesting that these individuals may be at increased risk for coronary heart disease at a young age. The objective of the present study was to evaluate subclinical atherosclerosis among women with PCOS and age-matched control subjects. A total of 125 white PCOS cases and 142 controls, aged
30 years were recruited. Collection of baseline
sociodemographic data, reproductive hormone levels, and
cardiovascular risk factors was conducted from 1992 to
1994. During follow-up (1996 to 1999), these women underwent B-mode
ultrasonography of the carotid arteries for the evaluation of carotid
intima-media wall thickness (IMT) and the prevalence of plaque. A
significant difference was observed in the distribution of carotid
plaque among PCOS cases compared with controls: 7.2% (9 of 125) of
PCOS cases had a plaque index of 3 compared with 0.7% (1 of 142) of
similarly aged controls (P=0.05). Overall and in the
group aged 30 to 44 years, no difference was noted in mean carotid IMT
between PCOS cases and controls. Among women aged 45 years, PCOS
cases had significantly greater mean IMT than did control women
(0.78±0.03 versus 0.70±0.01 mm, P=0.005). This
difference remained significant after adjustment for age and BMI
(P<0.05). These results suggest that (1) lifelong
exposure to an adverse cardiovascular risk profile in
women with PCOS may lead to premature atherosclerosis,
and (2) the PCOS-IMT association is explained in part by weight and fat
distribution and associated risk factors. There may be an independent
effect of PCOS unexplained by the above variables that is related
to the hormonal dysregulation of this condition.
Key Words: cardiovascular risk factors • polycystic ovary syndrome • subclinical atherosclerosis • carotid intima-media wall thickness • B-mode duplex ultrasonography
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Polycystic ovary syndrome (PCOS), a reproductive endocrine disorder characterized by chronic anovulation, hyperandrogenism, hyperinsulinemia, and obesity, may represent one of the largest unique groups of women at high risk for the development of early onset coronary heart disease.1 PCOS affects
5% of all women.2
Over the past decade, it has been reported that women with PCOS exhibit
an increase in coronary heart disease risk factors, including
decreased levels of HDL cholesterol (HDLc), elevated
levels of LDL cholesterol (LDLc) and
triglycerides, increased prevalence of hypertension and
insulin resistance, and abnormalities in the coagulation and
fibrinolytic pathways.3 4 5 6 7 8 9 10 11 12 13 14 This profile is similar to the
metabolic cardiovascular syndrome (syndrome
X), which represents a clustering within an individual of
hyperinsulinemia, mild glucose intolerance,
dyslipidemia, and hypertension.15 Epidemiological studies in middle-aged and elderly populations have demonstrated greater carotid intima-media wall thickness (IMT) in association with an adverse cardiovascular risk profile, including higher levels of LDLc and triglycerides, increased abdominal adiposity, higher systolic blood pressure, and hyperinsulinemia. These characteristics are similar to those observed in PCOS.16 17 18 19 20 21 22 Carotid arteriosclerosis assessed by B-mode ultrasound has been shown to be a reliable measure of generalized atherosclerosis and has been positively associated with the prevalence and incidence of stroke and myocardial infarction.23 24 25 26 27 28 29 Hence, carotid ultrasound is an important tool that can be used to further characterize the cardiovascular risk in the PCOS population.
In a previous report, we presented detailed information on cardiovascular risk factors in the largest group of PCOS cases (244 women) and controls (244 women) studied to date.3 30 Compared with control women of similar age, women with PCOS exhibited significantly increased body mass index (BMI), LDLc, waist-to-hip ratio, fasting insulin, and systolic blood pressure and significantly lower levels of HDLc.
Risk profiles were also compared across 4 specific age groups: 19 to 24
years, 25 to 34 years, 35 to 44 years, and 45 years. After adjustment
for BMI, hormone use, and insulin levels, women with PCOS had
substantially higher LDLc and total cholesterol levels than
did controls in each age group <45 years. After the age of 45,
however, little difference was noted in risk factors between groups.
Because weight is recognized as a major determinant of coronary
heart disease risk, a further comparison of LDLc and other risk factors
was made between cases and controls stratified by age (<40 and 40
years) and BMI (<26 and 26 kg/mg2). In the
group aged <40 years, LDLc levels were significantly higher among both
thinner and heavier PCOS cases compared with controls of similar body
habitus, suggesting a PCOS effect independent of BMI in these younger
women. In the group aged 40 years, however, no difference in LDL
levels was observed between cases and controls with stratification by
BMI.30
Subsequently, Guzick et al31 conducted a pilot study in
this high-risk cohort to evaluate the development of subclinical
atherosclerosis as evidenced by greater carotid IMT.
Sixteen PCOS cases, aged 40 years, with a current testosterone level
>2 nmol/L, and 16 age-matched normally cycling controls were recruited
from the original study population to undergo duplex carotid scanning.
Cases demonstrated a significantly higher mean carotid IMT than did
controls (0.68 versus 0.62 mm, respectively; P=0.03).
However, no significant difference in the prevalence of carotid plaque
was evident between cases and controls.
The present study seeks to extend our investigation of subclinical
atherosclerosis in our PCOS population of white women
aged 30 years. We hypothesized that women with PCOS would have
greater carotid IMT and plaque than would controls and that the
increase could be linked to the adverse metabolic profile
observed in PCOS.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects
Women with PCOS were originally identified from the practice records of physicians in the Division of Reproductive Endocrinology at Magee-Women’s Hospital between 1970 and 1990. A clinical diagnosis of PCOS was made if there was (1) a history of chronic anovulation in association with (2) clinical evidence of androgen excess (hirsutism) or biochemical evidence of an elevated total testosterone concentration (>2.0 nmol/L) or with (3) a ratio of luteinizing hormone to follicle-stimulating hormone of >2.0. Of the 278 such women who lived within 50 miles of the clinic, 244 agreed to a clinical assessment of hormonal and cardiovascular status. Voter registration tapes and household directories were used to identify 244 age-matched control women. Detailed data collection and laboratory methodologies have been previously published.3
The subjects were recruited from participants in our initial
case-control study who were aged 30 years at the time of the
follow-up clinic visit (1996 to 1999).3 A total of 147
PCOS cases and 136 controls participated in the most recent clinic
assessment. The present analysis was confined to white
women.
Carotid Ultrasound Protocol
A Toshiba SSA-270A scanner equipped with a 5-MHz linear array
imaging probe was used. Sonographers scanned the right and left common
carotid artery, carotid bulb, and the first 1.5 cm of the internal and
external carotid arteries. For each location, the sonographer imaged
the vessel in multiple planes and then focused on the interfaces
required to measure IMT and also on any areas of focal plaque. The best
images were digitized for later scoring.
Trained readers measured the average IMT across 1-cm segments of the near and far walls of the distal common carotid artery, the far wall of the carotid bulb, and the internal carotid artery on both right and left sides. Measures from each location were then averaged to produce an overall measure of carotid IMT. A computerized reading program developed for the Cardiovascular Health Study and modified in Pittsburgh was used. Readers also scored the ultrasound images for plaque in the common carotid, carotid bulb, internal carotid, and external carotid. Plaque was defined as a distinct area protruding into the vessel lumen with at least 50% greater thickness than the surrounding areas. For each segment, the degree of plaque was graded as follows: 0, no plaque; 1, 1 small plaque <30% of vessel diameter; 2, 1 medium plaque between 30% and 50% of the vessel diameter or multiple small plaques; and 3, 1 large plaque >50% of the vessel plaque or multiple plaques with at least 1 medium plaque. The grades were summed across right and left carotid arteries to create an overall measure of the extent of focal plaque called the plaque index. The plaque index has been used as a measure of focal plaque for a number of years and has been found to be a valid and reproducible measure of carotid atherosclerosis in a number of populations.
Reproducibility of carotid IMT and the plaque index was assessed in 5 women who underwent 2 ultrasound examinations within 1 week. Two separate sonographers scanned these women; 2 readers also scored each scan. When accounting for sonographer and reader variation, the intraclass correlation was 0.86 for IMT and 0.96 for the plaque index.
Statistical Analysis
All statistical analyses were performed by using SPSS
(version 10.0). Baseline risk factors collected during the l992 to 1994
clinic visit were used to predict current IMT and carotid plaque
evaluated by ultrasound during the l996 to 1999 clinical assessment.
Demographic, hormonal, and lipid data were available for
analysis from the original sample as previously
reported.3 Descriptive statistics, including measures of
central tendency and dispersion, were computed for PCOS cases and
controls and compared by use of a t test for independent
samples for continuous data or a 
2 test for
categorical data. Nonnormally distributed continuous data were
logarithmically transformed before performing statistical comparisons
for triglyceride, insulin, and testosterone levels. The
distribution of carotid IMT was also markedly skewed. Thus, a
reciprocal exponential transformation was performed to normalize the
distribution of carotid IMT for statistical comparisons and regression
modeling. Because the reciprocal transformation results in ß values
that are in the opposite direction from the associations noted between
the risk variables and the raw IMT, the ß values were multiplied
by -1 for ease of interpretation. Additionally, age- and BMI-adjusted
means were estimated and compared for cardiovascular
risk factors and IMT by use of a general linear model.
Linear regression modeling was used to identify the independent
baseline cardiovascular risk factors that predicted IMT
as the dependent continuous variable. The use of baseline rather
than concurrent risk variables as predictors of subclinical
atherosclerosis, a chronic disease outcome with a long
latency, was selected as the most appropriate modeling strategy.
Cardiovascular predictors explored in these
analyses included age, BMI, waist-to-hip ratio,
systolic and diastolic blood pressure, LDLc, HDLc,
triglycerides, fasting insulin, total testosterone, smoking
status, and hormone use. Additionally, stratification by age and BMI
was used to better assess the potential confounding effect of obesity
on IMT. All analyses were conducted by use of the linear
regression module in SPSS. Regression models were constructed for the
total population and for subgroups stratified by age <45 and 45
years.
Exploratory univariate regressions of carotid IMT with specific cardiovascular risk factors were conducted. In multivariate regression modeling, the effect of PCOS on carotid IMT independent of age, BMI, and those cardiovascular risk factors found to be significant in the univariate regression analysis was assessed.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
A total of 125 white PCOS cases and 142 controls underwent carotid ultrasonographic scanning. Baseline sociodemographic and reproductive factors for PCOS cases and controls obtained during the initial clinic visit (1992 to 1994) are shown in Table 1
. Cases and controls were similar
in general characteristics. At baseline, however, PCOS cases were
slightly younger than controls (37.5 years versus 39.0 years,
respectively; P=0.05), and cases had fewer pregnancies.
|
Selected cardiovascular risk factors in the PCOS cases
and controls are shown in Table 2.
Significant differences were noted in several baseline characteristics,
including mean BMI, waist-to-hip ratio, total cholesterol,
HDLc, insulin, triglyceride levels, and systolic
blood pressure. Diastolic blood pressure was not
significantly different between groups, and LDLc was of borderline
significance. Total testosterone and androstenedione levels were
significantly higher in cases than controls. There was also a
significant difference noted in the ratio of luteinizing hormone to
follicle-stimulating hormone. These results are similar to those
reported for the total cohort of 244 cases and 244
controls.3 To control for possible confounding, age- and
BMI-adjusted analyses were also carried out. Mean adjusted
values for each of the biochemical parameters are also
presented. The results were similar, except that
systolic blood pressure and total cholesterol were
no longer significantly different between cases and controls.
|
Twenty-seven of 125 cases (21.6%) had ultrasonographic evidence of
atherosclerotic plaque compared with 22 (15.5%) control women
(P=0.050, Table 3). Of the 27
cases with plaque, 14 women had a plaque index of 1, 4 had a plaque
index of 2, and 9 had a plaque index of 3. Among the controls, 16
women had a plaque index of 1, 5 had an index of 2, and 1 of the
controls had an index of 3. Among women aged 45 years, the
proportion with a plaque index of 3 was also markedly greater in PCOS
cases than in controls (14.9% versus 0.0%, P=0.002).
|
No significant differences in carotid IMT were noted between cases and
controls (P=0.299) in the total group (Table 4). In the group aged 30 to 44 years, no
significant difference was noted in carotid IMT between PCOS cases and
controls. Among women aged 45 years, PCOS cases had significantly
greater IMT than did control women (0.78±0.03 versus 0.70±0.01
mm, respectively; P=0.005). A significant interaction was
noted between PCOS and age in the extent of carotid IMT
(P=0.031, Figure).
|
|
The mean BMI for PCOS cases and controls aged 30 to 44 years was not
significantly different (29.0±0.86 and 27.1±0.73
kg/m2, respectively; P=0.08). However,
among cases and controls aged 45 years, a significant difference
existed in mean BMI (31.9±1.3 and 25.8±0.69
kg/m2, respectively; P<0.001). Hence,
age- and BMI-adjusted IMT means were calculated (Table 4
).
Adjusted IMT averages were 0.77±0.02 mm (95% CI 0.74 to 0.81)
and 0.71±0.02 mm (95% CI 0.68 to 0.75) for cases and controls
aged 45 years, respectively. This difference in IMT remained
statistically significant even after adjustment
(P<0.05).
In the women aged <45 years, there was little evidence of any greater
subclinical atherosclerosis in PCOS cases versus
controls, regardless of BMI subgroup or case status (Table 5). In the group aged 45
years, higher BMI was associated with greater extent of carotid IMT
among PCOS cases (0.75 versus 0.80 mm). The BMI effect is less
evident in older control women (0.70 versus 0.72 mm). In the
thinner subgroup aged 45 years, PCOS women (mean BMI 21.7
kg/m2) had a 0.05 mm greater IMT than was
observed in thinner control women of similar BMI (22.7
kg/m2; 7.1% difference, P=0.219).
Among women aged 45 years with a BMI 26
kg/m2, a significant difference was noted in IMT
between PCOS cases and controls (0.80 versus 0.72 mm,
respectively; P=0.04). However, BMI was also higher among
cases than controls (36.2 and 32.5 kg/m2,
respectively) in this subgroup. When analysis was restricted to
women with a BMI <40 kg/m2 to eliminate the body
size difference between cases and controls (31.9 and 31.3
kg/m2, respectively), although the numbers are
smaller, the mean IMT remained greater in PCOS cases compared with
controls (0.79±0.21 versus 0.72±0.10 mm, respectively;
P=0.15).
|
Univariate linear regressions of IMT with selected
cardiovascular risk factors are shown in Table 6. In the total group and in the group
aged <45 years, several cardiovascular risk factors
were found to be significantly associated with IMT, including age, BMI,
diastolic and systolic blood pressures,
waist-to-hip ratio, and triglycerides
(P<0.05).
|
Conversely, in women aged 45 years, PCOS was a highly significant
predictor of IMT (P=0.003). Of the traditional
cardiovascular risk factors, BMI, LDLc, insulin,
systolic blood pressure, and triglycerides were
also significant predictors in this age group (all P<0.03).
Hormone use and smoking status were not associated with IMT in the
total group or in the age-stratified subgroups.
Multivariate linear regression models were carried out
to assess the independent effect of PCOS on IMT adjusted for age, BMI,
and cardiovascular risk factors found to be associated
with IMT in the univariate analyses (LDLc,
systolic and diastolic blood pressures, insulin,
triglycerides, and waist-to-hip ratio). Results are
presented in Table 7. In the
total sample, after adjusting for age and BMI, PCOS was not a
significant predictor of carotid IMT (P=0.337). Subsequent
addition of the other cardiovascular risk factors in
separate models for the total group did not alter the PCOS-IMT
relationship. Systolic blood pressure in the total sample was
the only significant predictor of carotid IMT (P=0.023).
Diastolic blood pressure and triglyceride
levels were of borderline significance (P=0.082 and
P=0.078, respectively). In the group aged <45 years, PCOS
status was not significant in any model. Systolic and
diastolic blood pressures were related to carotid IMT in
this subgroup (P<0.05), and triglyceride level
was of borderline significance (P=0.066).
|
In the group aged 45 years, PCOS was a significant predictor or IMT
(P=0.042), independent of age and BMI. With the addition of
LDLc, the association between PCOS and IMT became more significant
(P=0.024). LDLc itself was a significant predictor in this
older age group (P=0.048). LDLc and PCOS both exerted an
independent effect on IMT independent of age and BMI. Similarly, with
the addition of systolic or diastolic blood
pressure or triglycerides in separate models, the PCOS-IMT
relationship remained of borderline significance (P=0.068 to
0.088). Notably, the inclusion of log insulin or waist-to-hip ratio
eliminated the significance of PCOS as an independent predictor of
carotid IMT in the group aged 45 years (Table 7).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
PCOS is characterized by a clustering of risk factors (eg, greater body mass, waist-to-hip ratio, and fasting insulin levels and diabetes) that is associated with an adverse lipid profile and high blood pressure. Carotid artery wall thickness has been shown in numerous studies to be strongly associated with obesity, waist-to-hip ratio, and lipids.16 17 18 19 20 21 22 In the present study, carotid IMT was investigated as a potential marker of cardiovascular disease (CVD) risk in PCOS.
In the present study, a difference between PCOS cases and
controls in carotid IMT was observed in older women (aged 45 years)
but not in younger women. Because CVD is characterized by a long
incubation period, the metabolic alterations observed in
younger PCOS women appear to translate into measurable carotid
abnormalities by middle age. Moreover, PCOS and age appear to interact
to adversely impact carotid wall thickness to a significantly greater
degree than that observed with aging alone. Among 200 participants in
the Healthy Women’s Study (HWS) who underwent B-mode ultrasound of the
carotid arteries, the mean IMT was 0.76±0.11 mm, which is similar
to that observed in our PCOS subgroup aged 45 years.18
However, the participants in the HWS were significantly older at the
time of the carotid evaluation compared with the women with PCOS in
this cohort (57.0 versus 49.6 years, respectively). This unfavorable
influence of PCOS on carotid IMT in middle age is notable, inasmuch as
the difference in lipid levels between PCOS cases and controls appears
to narrow as women approach the menopausal transition.30
From these data, one might speculate that longstanding exposure to an
adverse cardiovascular profile among women with PCOS at
an early age leads to premature subclinical atherosclerotic
changes.
Further evidence in support of premature atherosclerotic changes in
PCOS can be seen in the comparison of the proportions of cases and
controls with a mean IMT of >0.75 mm. Bonithon-Kopp et
al20 proposed this definition of carotid IMT as a
definition of subclinical disease. A total of 44.7% of the PCOS cases
aged 45 years met this criterion for atherosclerosis
compared with 15% of similarly aged controls
(P<0.001).
In any attempt to evaluate the potential independent association of PCOS with CVD, obesity is a powerful confounding influence. Weight and BMI, as well as waist circumference, have been associated with increased subclinical atherosclerosis in several recent studies.21 22 32 33 In the present study as well, BMI was a powerful predictor of IMT, particularly in women with PCOS. In the stratified analysis, IMT was greater in thin and heavy women with PCOS compared with controls of similar size.
We also addressed the issue of which, if any, of the traditional cardiovascular risk factors could be "substituted" for PCOS to explain the apparent effect of this disorder observed in our older subgroup. When PCOS was entered as a univariate predictor of the transformed IMT variable, the regression coefficient was 0.286 (P=0.003). Controlling for age and BMI slightly altered the PCOS association (ß=0.206, P=0.042). Additionally, adjusting for LDL, systolic or diastolic blood pressure, or triglycerides reduced the regression coefficient only slightly; the P value for PCOS as a predictor of IMT remained of borderline significance (P=0.024 to 0.09).
However, fasting insulin and waist circumference or waist-to-hip
ratio appeared to attenuate the relationship of PCOS and IMT,
suggesting that at least part of the observed association of PCOS and
IMT in middle-aged PCOS women may be driven by central obesity and
hyperinsulinemia. Insulin enhances
cholesterol transport into arteriolar smooth muscle cells
and increases the proliferation and cholesterol synthesis
of these cells.34 Hyperinsulinemia has
been found to be related to increased IMT in several previous
studies.17 35 It is possible that the apparent association
of PCOS with IMT may also be mediated by factors related to
hyperinsulinemia and central obesity, such as
plasminogen activator inhibitor-1,
C-reactive protein, and tumor necrosis
factor-
.13 14 36 37
The major strengths of the present study include a well-characterized relatively large PCOS cohort of older and younger women as well as a 6- to 7-year follow-up from baseline risk factor measurement to subclinical disease assessment. These older PCOS women represent a unique group to monitor disease progression. However, study limitations exist. A longer period of follow-up is necessary, particularly in younger PCOS women, to confirm the progression of IMT as the cohort ages. In addition, subgroup analysis was limited by sample size considerations, especially in the group aged >45 years.
In clinical practice, women with PCOS are seen primarily for menstrual irregularity, androgen excess, and infertility. Treatment is traditionally targeted at the immediate presenting complaint. If the issues of menstrual dysfunction and infertility are resolved, these women may seek no further treatment. However, women with PCOS, because of the underlying pathophysiology (ie, aberrant sex-steroid hormone metabolism and insulin resistance) and/or associated elevated CVD risk factors, may be at high risk of CVD or cerebrovascular disease,38 which may be prevented by pharmacological or nonpharmacological therapies. It is still not determined whether PCOS carries an increased risk of CVD above that due to obesity and body fat distribution and associated CVD risk factors. The results of the present study suggest that much of the excess risk may indeed be explained by the traditional known risk factors. To that end, weight control and physical activity may play an important role in risk management in PCOS. However, there may also be an independent effect of PCOS on IMT that may be mediated by low peak estradiol levels or hormonal dysregulation. Given the apparent increase of subclinical disease even in thinner PCOS cases, the use of insulin-lowering drugs in younger women with PCOS, reported in short-term studies to have a beneficial effect on endocrine parameters and lipid levels, should be investigated as a long-term means of reducing the later life risk of CVD.
|
Acknowledgments |
|---|
This study was supported by National Institutes of Health grant HL-44664.
|
Footnotes |
|---|
Reprint requests to Evelyn O. Talbott, DrPH, Department of Epidemiology, University of Pittsburgh, 130 DeSoto St, GSPH/A544 Crabtree Hall, Pittsburgh, PA 15261.
Consulting Editor for this article was Alan M. Fogelman, MD.
Received May 15, 2000; accepted August 22, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Franks S. Polycystic ovary syndrome. N Engl J Med.. 1995;333:83–86.
2.
Knochenhauer ES, Key TJ, Kahsar-Miller M,
Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary
syndrome in unselected black and white women of the southeastern United
States: a prospective study. J Clin Endocrinol
Metabolism.. 1998;83:3078–3082.
3.
Talbott E, Guzick D, Clerici A, Berga S, Detre
K, Weimer K, Kuller L. Coronary heart disease risk factors in
women with polycystic ovary syndrome. Arterioscler Thromb Vasc
Biol. 1995;15:821–827.
4. Mattson L, Culberg G, Hamberger L, Samsioe G, Silfverstolpe G. Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk of coronary heart disease. Fertil Steril. 1984;42:579–584.[Medline] [Order article via Infotrieve]
5.
Wild R, Painter P, Coulson P, Carruth K, Ranney
G. Lipoprotein lipid concentrations and cardiovascular
risk in women with polycystic ovary syndrome. J Clin
Endocrinol Metab. 1985;61:946–951.
6. Chang RJ, Nakamura R, Judd H, Kaplan S. Insulin resistance in non-obese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;51:356–359.
7. Gibson M, Schiff I, Tulchindky D, Ryan KJ. Characterization of hyperandrogenism with insulin-resistance diabetes type A. Fertil Steril. 1980;33:501–505.[Medline] [Order article via Infotrieve]
8. Pasquali R, Venturoli S, Paradis R, Capelli M, Parenti M, Melchionda N. Insulin and C-peptide levels in obese patients with polycystic ovaries. Horm Metab Res. 1982;14:284–287.[Medline] [Order article via Infotrieve]
9. Slowinska-Szrednicka J, Zgliczynski S, Wierzbicki M, Szrednicki M, Stopinska-Gluszak U, Zgliczynski W, Soszynski P, Chotkowska E, Bednarska M, Sadowaki Z. The role of hyperinsulinemia in the development of lipid disturbances in non-obese and obese women with polycystic ovary syndrome. J Endocrinol Invest. 1991;14:569–575.[Medline] [Order article via Infotrieve]
10. Wild R, Alaupovic P, Givens J, Parker I. Lipoprotein abnormalities in hirsute women. Am J Obstet Gynecol. 1992;167:1813–1818.[Medline] [Order article via Infotrieve]
11. Wild R, Alaupovic P, Parker I. Lipid and apolipoprotein abnormalities in hirsute women. Am J Obstet Gynecol. 1992; 167:1191–1197.
12. Conway G, Argawal D, Betteridge, Jacobs H. Risk Factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol. 1992;37:119–125.[Medline] [Order article via Infotrieve]
13. Talbott EO, Zborowski JV, Guzick DS, Meilahn EN, Tracy RP, McHugh KP, Kuller LH. Increased PAI-1 level in women with PCOS: evidence for a specific "PCOS effect" independent of age and BMI. Circulation.. 2000;101:716. Abstract.
14. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome fertility and sterility. 1998;69:236–241.
15. Reaven GM. Pathophysiology of insulin resistance in human disease: physiological reviews. 1995;75:473–486.
16.
Chambless LE, Heiss G, Folsom AR, Rosamond W,
Szkle M, Charrett AR, Clegg LX. Association of coronary heart
disease incidence with carotid arterial wall thickness and
major risk factors: the Atherosclerosis Risk in
Communities (ARIC) Study, 1987–1993. Am J Epidemiol. 1997;146:483–494.
17. Folsom AR, Eckfeldt JH, Weitzman S, Ma Jing, Chambless LE, Barnes RW, Cram KB, Hutchinson RG, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Stroke. 1994;25:66–73.[Abstract]
18.
Lassila HC, Tyrrell KS, Matthews KA, Wolfson SK,
Kuller LH. Prevalence and determinants of carotid
atherosclerosis in healthy postmenopausal women.
Stroke. 1997;28:513–517.
19.
Sutton-Tyrrell K, Alcorn HG, Herzog H, Kelsey SF,
Kuller LH. Morbidity, mortality, and antihypertensive treatment effects
by extent of atherosclerosis in older adults with
isolated systolic hypertension. Stroke. 1995;26:1319–1324.
20.
Bonithon-Kopp C, Scarabin P-Y, Taquet A, Touboul
P-J, Malmejac A, Guize L. Risk factors for early carotid
atherosclerosis in middle-aged French women.
Arterioscler Thromb. 1991;11:966–972.
21.
Dobs AS, Nieto FJ, Szklo M, Barnes R, Sharrett
AR, Ko W-J, for the ARIC Study Group. Risk factors for popliteal and
carotid wall thicknesses in the atherosclerosis risk in
communities (ARIC) study. Am J Epidemiol. 1999;150:1055–1067.
22. Folsom AR, Wu KK, Shahar E, Davis CE, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb. 193;13:1829–1836.
23.
Salonen Jukka T, Salonen R. Ultrasonographically
assessed carotid morphology and the risk of coronary heart
disease. Arterioscler Thromb. 1991;11:1245–1249.
24.
Burke GL, Evans GW, Riley WA, Sharrett AR, Howard
G, Barnes RW, Rosamond W, Crow RS, Rautaharju PM, Heiss G, for the ARIC
Study Group. Arterial wall thickness is associated with
prevalent cardiovascular disease in middle-aged adults:
the Atherosclerosis Risk in Communities (ARIC) Study.
Stroke. 1995;26:386–391.
25.
Bots ML, Hoew AW, Koudstaal PJ, Hofman A, Grobbee
DE. Common carotid intima-media thickness and risk of stroke and
myocardial infarction: the Rotterdam Study. Circulation. 1997;96:1432–1437.
26.
Chambless LE, Folsom AR, Clegg LX, Sharrett AR,
Shahar E, Nieto FJ, Rosamond WD, Evans G. Carotid wall thickness is
predictive of incident clinical stroke: the
Atherosclerosis Risk in Communities (ARIC) study.
Am J Epidemiol. 2000;151:478–487.
27.
Kuller LH, Shemanski L, Psaty BM, Borhani NO,
Gardin J, Haan MN, O’Leary DH, Savage PJ, Tell GS, Tracy R.
Subclinical disease as an independent risk factor for
cardiovascular disease. Circulation. 1995;92:720–726.
28.
O’Leary DH, Polak JF, Kronmal RA, Manolio TA,
Burke GL, Wolfson SK Jr, for the Cardiovascular Health
Study Collaborative Research Group. Carotid-artery intima and media
thickness as a risk factor for myocardial infarction and stroke in
older adults. N Engl J Med. 1999;340:14–22.
29.
Tonstad S, Joakimsen O, Stensland-Bugge E, Leren
TP, Ose L, Russell D, Bonaa KH. Risk factors related to carotid
intima-media thickness and plaque in children with familial
hypercholesterolemia and control subjects.
Arterioscler Thromb Vasc Biol. 1996;16:984–991.
30. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol. 1998;51:415–422.[Medline] [Order article via Infotrieve]
31. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol. 1996;174:1224–1229.[Medline] [Order article via Infotrieve]
32. Karason K, Wikstrand J, Sjostrom L, Wendelhag I. Weight loss and progression of early atherosclerosis in the carotid artery: a four-year controlled study of obese subjects. Int J Obes Relat Metab Disord. 1999;23:948–956.[Medline] [Order article via Infotrieve]
33. Ciccone M, Maiorano A, De Pergola G, Minenna A, Giorgino R, Rizzon P. Microcirculatory damage of common carotid artery wall in obese and non obese subjects. Clin Hemorheol Microcirc. 1999;21:365–374.[Medline] [Order article via Infotrieve]
34. Defronzo RA, Ferrannini E. Insulin resistance, a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194.[Abstract]
35.
Laakso M, Arlund H, Salonen R, Suhonen M, Pyorala
K, Salonen JT, Karhapaa P. Asymptomatic
atherosclerosis and insulin resistance.
Arterioscler Thromb. 1991;11:1068–1976.
36. Gonzalez F, Thusu K, Abedel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism. 1999;48:437–441.[Medline] [Order article via Infotrieve]
37. Fiotti N, Giansante C, Ponte E, Delbello C, Calabreses S, Zacchi T, Dobrina A, Guarnieri G. Atherosclerosis and inflammation: patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis. 199;145:51–60.
38. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with PCOS at long-term follow-up: a retrospective cohort study. Clin Endocrinol. 2000;522:595–600.
This article has been cited by other articles:
 |
|
 |
|
  M. Rizzo, K. Berneis, M. Hersberger, I. Pepe, G. Di Fede, G. B. Rini, G. A. Spinas, and E. Carmina Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype Hum. Reprod., September 1, 2009; 24(9): 2286 - 2292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.J. Goverde, A.J.B. van Koert, M.J. Eijkemans, E.A.H. Knauff, H.E. Westerveld, B.C.J.M. Fauser, and F.J. Broekmans Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria Hum. Reprod., March 1, 2009; 24(3): 710 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Hoeger Polycystic Ovary Syndrome, Inflammation, and Statins: Do We Have the Right Target? J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 35 - 37. [Full Text] [PDF]
|
|
|
|
|
|
T. Sathyapalan, E. S. Kilpatrick, A.-M. Coady, and S. L. Atkin The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 103 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Handelsman Metabolic Syndrome Pathophysiology and Clinical Presentation Toxicol Pathol, January 1, 2009; 37(1): 18 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel The Metabolic Syndrome Endocr. Rev., December 1, 2008; 29(7): 777 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hoeger, K. Davidson, L. Kochman, T. Cherry, L. Kopin, and D. S. Guzick The Impact of Metformin, Oral Contraceptives, and Lifestyle Modification on Polycystic Ovary Syndrome in Obese Adolescent Women in Two Randomized, Placebo-Controlled Clinical Trials J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4299 - 4306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.I. Ahmed, A.J. Duleba, O. El Shahat, M.E. Ibrahim, and A. Salem Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome Hum. Reprod., November 1, 2008; 23(11): 2564 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Jensterle, M. Sebestjen, A. Janez, J. Prezelj, T. Kocjan, I. Keber, and M. Pfeifer Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome Eur. J. Endocrinol., October 1, 2008; 159(4): 399 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Guzick Do Cardiovascular Risk Factors in Polycystic Ovarian Syndrome Result in More Cardiovascular Events? J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1170 - 1171. [Full Text] [PDF]
|
|
|
|
|
|
L. J. Shaw, C. N. Bairey Merz, R. Azziz, F. Z. Stanczyk, G. Sopko, G. D. Braunstein, S. F. Kelsey, K. E. Kip, R. M. Cooper-DeHoff, B. D. Johnson, et al. Postmenopausal Women with a History of Irregular Menses and Elevated Androgen Measurements at High Risk for Worsening Cardiovascular Event-Free Survival: Results from the National Institutes of Health--National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1276 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. U. Liepa, A. Sengupta, and D. Karsies Polycystic Ovary Syndrome (PCOS) and Other Androgen Excess-Related Conditions: Can Changes in Dietary Intake Make a Difference? Nutr Clin Pract, February 1, 2008; 23(1): 63 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Nestler Metformin for the Treatment of the Polycystic Ovary Syndrome N. Engl. J. Med., January 3, 2008; 358(1): 47 - 54. [Full Text] [PDF]
|
|
|
|
|
|
N. Sattar and S. M. Nelson Polycystic Ovarian Syndrome, Biomarkers, and Metformin: Research, Risk, and Reality J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 34 - 36. [Full Text] [PDF]
|
|
|
|
|
|
R. Shroff, A. Kerchner, M. Maifeld, E. J. R. Van Beek, D. Jagasia, and A. Dokras Young Obese Women with Polycystic Ovary Syndrome Have Evidence of Early Coronary Atherosclerosis J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4609 - 4614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Luque-Ramirez, C. Mendieta-Azcona, F. Alvarez-Blasco, and H. F. Escobar-Morreale Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome Hum. Reprod., December 1, 2007; 22(12): 3197 - 3203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Celik, I. Sahin, N. Celik, S. Hascalik, L. Keskin, H. Ozcan, A. Uckan, and F. Kosar Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study Hum. Reprod., November 1, 2007; 22(11): 2992 - 2998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Legro A 27-Year-Old Woman With a Diagnosis of Polycystic Ovary Syndrome JAMA, February 7, 2007; 297(5): 509 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Banaszewska, L. Pawelczyk, R. Z. Spaczynski, J. Dziura, and A. J. Duleba Effects of Simvastatin and Oral Contraceptive Agent on Polycystic Ovary Syndrome: Prospective, Randomized, Crossover Trial J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 456 - 461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Berneis, M. Rizzo, V. Lazzaroni, F. Fruzzetti, and E. Carmina Atherogenic Lipoprotein Phenotype and Low-Density Lipoproteins Size and Subclasses in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 186 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Chen, W.-S. Yang, J.-H. Yang, C. K. Hsiao, Y.-S. Yang, and H.-N. Ho Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS Hum. Reprod., September 1, 2006; 21(9): 2266 - 2271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Topcu, M. Caliskan, E. E. Ozcimen, D. Tok, A. Uckuyu, D. Erdogan, H. Gullu, A. Yildirir, H. Zeyneloglu, and H. Muderrisoglu Do young women with polycystic ovary syndrome show early evidence of preclinical coronary artery disease? Hum. Reprod., April 1, 2006; 21(4): 930 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Lewandowski, J. Komorowski, C. J. O'Callaghan, B. K. Tan, J. Chen, G. M. Prelevic, and H. S. Randeva Increased Circulating Levels of Matrix Metalloproteinase-2 and -9 in Women with the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1173 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Orio Jr., S. Palomba, T. Cascella, B. De Simone, F. Manguso, S. Savastano, T. Russo, A. Tolino, F. Zullo, G. Lombardi, et al. Improvement in Endothelial Structure and Function after Metformin Treatment in Young Normal-Weight Women with Polycystic Ovary Syndrome: Results of a 6-Month Study J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6072 - 6076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lakhani, A. Leonard, A.M. Seifalian, and P. Hardiman Microvascular dysfunction in women with polycystic ovary syndrome Hum. Reprod., November 1, 2005; 20(11): 3219 - 3224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Meyer, B. P. McGrath, and H. J. Teede Overweight Women with Polycystic Ovary Syndrome Have Evidence of Subclinical Cardiovascular Disease J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5711 - 5716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kravariti, K. K. Naka, S. N. Kalantaridou, N. Kazakos, C. S. Katsouras, A. Makrigiannakis, E. A. Paraskevaidis, G. P. Chrousos, A. Tsatsoulis, and L. K. Michalis Predictors of Endothelial Dysfunction in Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5088 - 5095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Vural, E. Caliskan, E. Turkoz, T. Kilic, and A. Demirci Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome Hum. Reprod., September 1, 2005; 20(9): 2409 - 2413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Meyer, B. P. McGrath, J. Cameron, D. Kotsopoulos, and H. J. Teede Vascular Dysfunction and Metabolic Parameters in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4630 - 4635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Second World Congress on the Insulin Resistance Syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy Diabetes Care, July 1, 2005; 28(7): 1821 - 1830. [Full Text] [PDF]
|
|
|
|
 |
|
 M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Kilicdag, T. Bagis, E. Tarim, E. Aslan, S. Erkanli, E. Simsek, B. Haydardedeoglu, and E. Kuscu Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial Hum. Reprod., June 1, 2005; 20(6): 1521 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Diamanti-Kandarakis, K Alexandraki, A Protogerou, C Piperi, C Papamichael, A Aessopos, J Lekakis, and M Mavrikakis Metformin administration improves endothelial function in women with polycystic ovary syndrome Eur. J. Endocrinol., May 1, 2005; 152(5): 749 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vryonidou, A. Papatheodorou, A. Tavridou, T. Terzi, V. Loi, I.-A. Vatalas, N. Batakis, C. Phenekos, and A. Dionyssiou-Asteriou Association of Hyperandrogenemic and Metabolic Phenotype with Carotid Intima-Media Thickness in Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2740 - 2746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vrbikova and D. Cibula Combined oral contraceptives in the treatment of polycystic ovary syndrome Hum. Reprod. Update, May 1, 2005; 11(3): 277 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sutton-Tyrrell, R. P. Wildman, K. A. Matthews, C. Chae, B. L. Lasley, S. Brockwell, R. C. Pasternak, D. Lloyd-Jones, M. F. Sowers, J. I. Torrens, et al. Sex Hormone-Binding Globulin and the Free Androgen Index Are Related to Cardiovascular Risk Factors in Multiethnic Premenopausal and Perimenopausal Women Enrolled in the Study of Women Across the Nation (SWAN) Circulation, March 15, 2005; 111(10): 1242 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A S T Bickerton, N Clark, D Meeking, K M Shaw, M Crook, P Lumb, C Turner, and M H Cummings Cardiovascular risk in women with polycystic ovarian syndrome (PCOS) J. Clin. Pathol., February 1, 2005; 58(2): 151 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Sepilian and M. Nagamani Effects of Rosiglitazone in Obese Women with Polycystic Ovary Syndrome and Severe Insulin Resistance J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 60 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Talbott, J. V. Zborowski, M. Y. Boudreaux, K. P. McHugh-Pemu, K. Sutton-Tyrrell, and D. S. Guzick The Relationship between C-Reactive Protein and Carotid Intima-Media Wall Thickness in Middle-Aged Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6061 - 6067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Talbott, J. V. Zborowski, J. R. Rager, M. Y. Boudreaux, D. A. Edmundowicz, and D. S. Guzick Evidence for an Association between Metabolic Cardiovascular Syndrome and Coronary and Aortic Calcification among Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5454 - 5461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Tarkun, B. C. Arslan, Z. Canturk, E. Turemen, T. Sahin, and C. Duman Endothelial Dysfunction in Young Women with Polycystic Ovary Syndrome: Relationship with Insulin Resistance and Low-Grade Chronic Inflammation J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5592 - 5596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Orio Jr., S. Palomba, T. Cascella, B. De Simone, S. Di Biase, T. Russo, D. Labella, F. Zullo, G. Lombardi, and A. Colao Early Impairment of Endothelial Structure and Function in Young Normal-Weight Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4588 - 4593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Guzick Cardiovascular Risk in PCOS J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3694 - 3695. [Full Text] [PDF]
|
|
|
|
|
|
F. Orio Jr., S. Palomba, L. Spinelli, T. Cascella, L. Tauchmanova, F. Zullo, G. Lombardi, and A. Colao The Cardiovascular Risk of Young Women with Polycystic Ovary Syndrome: An Observational, Analytical, Prospective Case-Control Study J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3696 - 3701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Legro, E. Myers, and for the Reproductive Medicine Network Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome? Hum. Reprod., August 1, 2004; 19(8): 1697 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Taponen, H. Martikainen, M.-R. Jarvelin, U. Sovio, J. Laitinen, A. Pouta, A.-L. Hartikainen, M. I. McCarthy, S. Franks, M. Paldanius, et al. Metabolic Cardiovascular Disease Risk Factors in Women with Self-Reported Symptoms of Oligomenorrhea and/or Hirsutism: Northern Finland Birth Cohort 1966 Study J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2114 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Boulman, Y. Levy, R. Leiba, S. Shachar, R. Linn, O. Zinder, and Z. Blumenfeld Increased C-Reactive Protein Levels in the Polycystic Ovary Syndrome: A Marker of Cardiovascular Disease J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2160 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Littleton-Kearney and P. D. Hurn Testosterone as a Modulator of Vascular Behavior Biol Res Nurs, April 1, 2004; 5(4): 276 - 285. [Abstract] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Definitions of the Insulin Resistance Syndrome: The 1st World Congress on the Insulin Resistance Syndrome Diabetes Care, March 1, 2004; 27(3): 824 - 830. [Full Text] [PDF]
|
|
|
|
|
|
H. F. Escobar-Morreale, J. I. Botella-Carretero, G. Villuendas, J. Sancho, and J. L. San Millan Serum Interleukin-18 Concentrations Are Increased in the Polycystic Ovary Syndrome: Relationship to Insulin Resistance and to Obesity J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 806 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Sheehan Polycystic Ovarian Syndrome: Diagnosis and Management Clin. Med. Res., February 1, 2004; 2(1): 13 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum. Reprod., January 1, 2004; 19(1): 41 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden The Endocrine Society Meeting: Topics in Insulin Sensitivity and Hypertension Diabetes Care, September 1, 2003; 26(9): 2679 - 2688. [Full Text] [PDF]
|
|
|
|
|
|
R. S. Legro Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association? Endocr. Rev., June 1, 2003; 24(3): 302 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Diamanti-Kandarakis, J.-P. Baillargeon, M. J. Iuorno, D. J. Jakubowicz, and J. E. Nestler A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1927 - 1932. [Full Text] [PDF]
|
|
|
|
|
|
F. C. W. Wu and A. von Eckardstein Androgens and Coronary Artery Disease Endocr. Rev., April 1, 2003; 24(2): 183 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Orio Jr., S. Palomba, S. Di Biase, A. Colao, L. Tauchmanova, S. Savastano, D. Labella, T. Russo, F. Zullo, and G. Lombardi Homocysteine Levels and C677T Polymorphism of Methylenetetrahydrofolate Reductase in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 673 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Taponen, H. Martikainen, M.-R. Jarvelin, J. Laitinen, A. Pouta, A.-L. Hartikainen, U. Sovio, M. I. McCarthy, S. Franks, and A. Ruokonen Hormonal Profile of Women with Self-Reported Symptoms of Oligomenorrhea and/or Hirsutism: Northern Finland Birth Cohort 1966 Study J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 141 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Randeva, K. C. Lewandowski, J. Drzewoski, K. Brooke-Wavell, C. O'Callaghan, L. Czupryniak, E. W. Hillhouse, and G. M. Prelevic Exercise Decreases Plasma Total Homocysteine in Overweight Young Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4496 - 4501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Seli and A. J. Duleba Should patients with polycystic ovarian syndrome be treated with metformin? Hum. Reprod., September 1, 2002; 17(9): 2230 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. O. Yildiz, I. C. Haznedaroglu, S. Kirazli, and M. Bayraktar Global Fibrinolytic Capacity Is Decreased in Polycystic Ovary Syndrome, Suggesting a Prothrombotic State J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3871 - 3875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Nestler Should patients with polycystic ovarian syndrome be treated with metformin?: An enthusiastic endorsement Hum. Reprod., August 1, 2002; 17(8): 1950 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Solomon, F. B. Hu, A. Dunaif, J. E. Rich-Edwards, M. J. Stampfer, W. C. Willett, F. E. Speizer, and J. E. Manson Menstrual Cycle Irregularity and Risk for Future Cardiovascular Disease J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2013 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Legro, R. Bentley-Lewis, D. Driscoll, S. C. Wang, and A. Dunaif Insulin Resistance in the Sisters of Women with Polycystic Ovary Syndrome: Association with Hyperandrogenemia Rather Than Menstrual Irregularity J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2128 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Chronic Hyperandrogenic Anovulation and Premature Atherosclerosis Journal Watch Women's Health, January 9, 2001; 2001(109): 6 - 6. [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||